Literature DB >> 8240734

Non-antibody immunotherapy of cancer.

P B Chapman1, A N Houghton.   

Abstract

Immunotherapeutic agents have become important additions to the list of anti-cancer treatments; further progress will require more information about how the immune system can respond to tumor cells. Tumor cells can avoid eliciting an immune response through several mechanisms. Understanding these mechanisms may suggest strategies to manipulate tumor cells so that they trigger an effective immune response. Another strategy being developed is to improve the therapeutic index of cytokines so that better anti-tumor effects can be elicited with less toxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8240734     DOI: 10.1016/0952-7915(93)90128-f

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  4 in total

Review 1.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

Review 2.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

3.  The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells.

Authors:  A Thanhäuser; A Böhle; B Schneider; N Reiling; T Mattern; M Ernst; H D Flad; A J Ulmer
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

4.  Bacillus Calmette-Guérin in the management of superficial bladder cancer.

Authors:  Rakesh Kapoor; Vivek Vijjan; Pratipal Singh
Journal:  Indian J Urol       Date:  2008-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.